January 14, 2009
New analysis of more than 100,000 Medicaid patients suggests that while most psychiatrists are aware of the metabolic risks associated with second-generation antipsychotic medication, and the need to therefore monitor blood glucose and lipid levels, most patients are not screened.
Only approximately 25% of Medicaid patients received blood glucose level tests and 10% of patients had lipid levels tested.
The American Diabetes Association and American Psychiatric Association previously described the metabolic risks associated with second-generation antipsychotics and outlined a monitoring practice for patients. The protocol includes taking baseline assessment of personal/family history, weight, waist circumference, blood pressure, fasting glucose level and fasting lipid profile.